Vicore Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

STOCKHOLM, SE / ACCESS Newswire / February 18, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will present at the Oppenheimer 36^th Annual Healthcare Life Sciences Conference:

• Location: Virtual

• Format: Presentation and 1×1 meetings

• Presentation Date and Time: Wednesday, February 25 at 4:00 PM EST

• Webcast: Link

• Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.

Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com

Attachments
Vicore Pharma to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SOURCE: Vicore Pharma Holding